175
Participants
Start Date
March 31, 2010
Primary Completion Date
November 30, 2011
Study Completion Date
November 30, 2011
natalizumab
300 mg intravenous every 4 weeks
interferon beta 1-a
30 ug intramuscular once per week
methylprednisolone
1000 mg intravenous every 4 weeks
IV placebo
placebo intravenous every 4 weeks
glatiramer acetate
20 mg subcutaneous once daily
Research Site, Dresden
Research Site, Boston
Research Site, Boston
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Patchogue
Research Site, Latham
Research Site, Buffalo
Research Site, Hennigsdorf
Research Site, Hamburg
Research Site, Raleigh
Research Site, Charlotte
Research Site, Málaga
Research Site, El Palmar
Research Site, Atlanta
Research Site, Atlanta
Research Site, Pompano Beach
Research Site, Marburg
Research Site, Cullman
Research Site, Cleveland
Research Site, Bochum
Research Site, Valencia
Research Site, Valencia
Research Site, Des Moines
Research Site, Lake Barrington
Research Site, Chicago
Research Site, Freiburg im Breisgau
Research Site, München
Research Site, Salt Lake City
Research Site, San Francisco
Research Site, Seattle
Research Site, Fort Collins
Research Site, Uniontown
Lead Sponsor
Collaborators (1)
Elan Pharmaceuticals
INDUSTRY
Biogen
INDUSTRY